Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C, Kinderman P, Griffioen L, Rensing O, Labrie C, van den Wollenberg DJM, Hoeben RC, Coffey M, Loghmani H, Verdegaal EME, Welters MJP, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. Cancer Immunol Res. 2024 Mar 4;12(3):334-349. doi: 10.1158/2326-6066.CIR-23-0480. Cancer Immunol Res. 2024. PMID: 38194598 Free PMC article.
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ. Berkeley RA, et al. Among authors: van den wollenberg djm. Cancer Immunol Res. 2018 Oct;6(10):1161-1173. doi: 10.1158/2326-6066.CIR-18-0309. Epub 2018 Sep 12. Cancer Immunol Res. 2018. PMID: 30209061 Free article.
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Groeneveldt C, Kinderman P, van Stigt Thans JJC, Labrie C, Griffioen L, Sluijter M, van den Wollenberg DJM, Hoeben RC, den Haan JMM, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. J Immunother Cancer. 2022 Jul;10(7):e004464. doi: 10.1136/jitc-2021-004464. J Immunother Cancer. 2022. PMID: 35853671 Free PMC article.
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C, van Ginkel JQ, Kinderman P, Sluijter M, Griffioen L, Labrie C, van den Wollenberg DJM, Hoeben RC, van der Burg SH, Ten Dijke P, Hawinkels LJAC, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. Cancer Res Commun. 2023 Feb 23;3(2):325-337. doi: 10.1158/2767-9764.CRC-23-0019. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36860656 Free PMC article.
Arming oncolytic reovirus with GM-CSF gene to enhance immunity.
Kemp V, van den Wollenberg DJM, Camps MGM, van Hall T, Kinderman P, Pronk-van Montfoort N, Hoeben RC. Kemp V, et al. Among authors: van hall t, van den wollenberg djm. Cancer Gene Ther. 2019 Sep;26(9-10):268-281. doi: 10.1038/s41417-018-0063-9. Epub 2018 Nov 23. Cancer Gene Ther. 2019. PMID: 30467340
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C, Kinderman P, van den Wollenberg DJM, van den Oever RL, Middelburg J, Mustafa DAM, Hoeben RC, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: van den wollenberg djm. J Immunother Cancer. 2020 Oct;8(2):e001191. doi: 10.1136/jitc-2020-001191. J Immunother Cancer. 2020. PMID: 33082167 Free PMC article.
Modification of mammalian reoviruses for use as oncolytic agents.
Van Den Wollenberg DJ, Van Den Hengel SK, Dautzenberg IJ, Kranenburg O, Hoeben RC. Van Den Wollenberg DJ, et al. Expert Opin Biol Ther. 2009 Dec;9(12):1509-20. doi: 10.1517/14712590903307370. Expert Opin Biol Ther. 2009. PMID: 19916732 Review.
35 results